Overview

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy on clinical symptoms, mucosal histology and endoscopic mucosal appearance of two doses of SR140333B against placebo in patients with mild to moderate ulcerative colitis resistant to treatment with 5-ASA.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi